MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.urolonc.2025.110989

Медицинская библиотека · Urologic oncology · 2026

Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma.

Tsimafeyeu Ilya, Guliyev Fuad, Ongarbayev Bakytzhan, Musaeva Gunel, Abdrakhmanov Ramil, Chubenko Vyacheslav, Baklanova Olga, Zukov Ruslan, Petkau Vladislav, Kaidarova Dilyara

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Patterns of progression under immuno-oncology regimens in metastatic renal cell carcinoma (mRCC) remain poorly described. This study characterizes site-specific disease progression in patients receiving first-line dual immunotherapy or immunotargeted therapy.

METHODS

This retrospective, observational cohort study included patients with clear-cell metastatic renal cell carcinoma treated between 2018 and 2024 with standard-dose regimens of nivolumab-ipilimumab (IO-IO) or pembrolizumab-axitinib and avelumab-axitinib combinations (IO-axitinib). The primary endpoint was the occurrence of new metastatic lesions at progression. Secondary endpoints included progression by >20% increase in target lesion size.

RESULTS

Of 334 patients identified, 233 were evaluable for analysis. Radiographic progression occurred in 86.3% of IO-IO and 60% of IO-axitinib. Development of new metastatic lesions was more frequent with Nivo-Ipi (39.3% vs. 22.2%), most commonly involving the lungs and bones. In contrast, IO-axitinib combinations showed a greater propensity for progression through enlargement of pre-existing lesions (77.8% vs. 60.7%), accompanied by the emergence of new adrenal gland metastases. Across both treatment groups, lymph nodes emerged as the most frequent new site of disease progression.

CONCLUSIONS

Nivo-Ipi was associated with more frequent development of new metastatic lesions, particularly in the lungs, bones, and lymph nodes, while axitinib-based combinations more often resulted in regrowth of existing disease with higher rates of adrenal involvement.

Для цитирования: Tsimafeyeu Ilya, Guliyev Fuad, Ongarbayev Bakytzhan, Musaeva Gunel, Abdrakhmanov Ramil, Chubenko Vyacheslav, Baklanova Olga, Zukov Ruslan, Petkau Vladislav, Kaidarova Dilyara. Distinct pathways of disease progression with dual checkpoint blockade versus immunotargeted therapy in metastatic renal cell carcinoma.. Urologic oncology. 2026. DOI: 10.1016/j.urolonc.2025.110989.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.